To evaluate the pharmacokinetics , safety and survival of trabectedin , metabolized primarily by cytochrome P450 ( CYP ) 3A4 enzyme , when coadministered with rifampin ( CYP3A4 inducer ) or ketoconazole ( CYP3A4 inhibitor ) in adult patients with advanced solid tumors .